Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Oncology

The Three Faces of Bone Sarcoma: Understanding Your Subtype

At a Glance

There are three main subtypes of primary bone sarcoma: osteosarcoma, Ewing sarcoma, and chondrosarcoma. They differ significantly in who they affect, where they grow, their genetic drivers, and how they are treated. Your exact subtype and genetic markers determine your treatment path.

While all bone sarcomas begin in the skeletal system, they are not all the same. Your treatment path is primarily dictated by your subtype—the specific kind of cell the cancer resembles and the genetic “instruction manual” that drives its growth. Understanding whether you have Osteosarcoma, Ewing Sarcoma, or Chondrosarcoma helps you and your care team choose the most effective tools to fight it.

Osteosarcoma: The Bone-Builder

Osteosarcoma is the most common primary bone cancer and is characterized by the production of osteoid (immature bone) by the cancer cells [1][2].

  • Who it affects: It most often strikes children, adolescents, and young adults (ages 10–30) during periods of rapid growth [2][3].
  • Where it appears: About 80% of cases occur around the knee (the lower femur or upper tibia) or in the upper arm (humerus) [4].
  • The Biology: Most osteosarcomas are “genetically messy,” meaning they have many complex changes. However, two of the most common drivers are mutations in the TP53 and RB1 genes, which normally act as the cell’s “brakes” to prevent cancer [5][6][7].
  • Treatment approach: It is typically treated with a “sandwich” approach: intensive chemotherapy to shrink the tumor, followed by surgery, and then more chemotherapy [8][9][10].

Ewing Sarcoma: The Genetic Switch

Ewing Sarcoma is the second most common bone cancer in children and young adults [11][12]. Unlike osteosarcoma, which looks like bone, Ewing sarcoma is made of “small round blue cells” that can appear in the bone or the surrounding soft tissue [13].

  • Who it affects: Most common in kids and teens, but it can occur in adults [12][14].
  • Where it appears: It is often found in the “shaft” (middle) of long bones like the femur, or in the pelvis and chest wall [4].
  • The Biology: Ewing sarcoma is almost always caused by a specific genetic “mistake” called a translocation. In about 85% of cases, pieces of chromosomes 11 and 22 swap places, creating a new, abnormal gene called EWSR1::FLI1 [15][16][17]. This gene acts like a permanent “on” switch for cell growth [18][19].
  • Treatment approach: This subtype is highly chemosensitive, meaning it often responds very well to chemotherapy [14][20]. Treatment involves aggressive chemotherapy, surgery, and sometimes radiation [21][22].

Chondrosarcoma: The Cartilage-Former

Chondrosarcoma is the rarest of the three and is distinct because it produces cartilage rather than bone [12].

  • Who it affects: This is primarily a cancer of adults, typically those over age 40 [12][23].
  • Where it appears: It is most common in the pelvis, hip (proximal femur), and shoulder (humerus) [24][25].
  • The Biology: Many chondrosarcomas carry mutations in the IDH1 or IDH2 genes [21]. These mutations change the cell’s metabolism, helping the cancer survive and grow.
  • Treatment approach: Chondrosarcoma is generally chemoresistant and radioresistant, meaning traditional chemotherapy and radiation are usually not effective [21]. Therefore, surgery is the primary and most important treatment to remove the tumor entirely [21].

Summary Table: Quick Comparison

Feature Osteosarcoma Ewing Sarcoma Chondrosarcoma
Typical Age 10–30 years [2] 5–25 years [12] Over 40 years [23]
Common Site Knee, Shoulder [4] Pelvis, Long bones [4] Pelvis, Hip, Shoulder [24]
Genetic Driver TP53, RB1 mutations [5] EWSR1 Translocation [15] IDH1/2 mutations [21]
Chemosensitive? Yes [10] Highly Yes [14] No (usually) [21]
Main Treatment Chemo + Surgery [8] Chemo + Surgery/Radiation [20] Surgery [21]

Common questions in this guide

What are the main types of bone sarcoma?
The three most common primary bone sarcomas are osteosarcoma, Ewing sarcoma, and chondrosarcoma. Each subtype originates from a different type of cell and behaves differently in the body.
Why does my age matter for a bone cancer diagnosis?
Different bone sarcomas tend to affect specific age groups. Osteosarcoma and Ewing sarcoma most often occur in children and young adults during periods of rapid bone growth, while chondrosarcoma primarily affects adults over age 40.
Is chemotherapy used for all bone sarcomas?
No, chemotherapy is not used for every subtype. While osteosarcoma and Ewing sarcoma generally respond very well to chemotherapy, chondrosarcoma is highly resistant to it, making surgery the primary and most important treatment.
Why does the pathology report look for genetic markers like EWSR1 or IDH?
Genetic markers tell doctors what acts as the 'engine' driving your tumor's growth. For example, Ewing sarcoma is driven by an EWSR1 gene translocation, while chondrosarcomas often have IDH mutations. Identifying these markers helps confirm your exact subtype.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the exact name and grade of my sarcoma subtype?
  2. 2.Did the pathology report mention specific genetic markers like an EWSR1 fusion or IDH mutation?
  3. 3.How does the location of my tumor (e.g., pelvis vs. leg) affect my surgical and treatment options?
  4. 4.How does my age play a role in the treatment plan you are recommending?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017.

    Cole S, Gianferante DM, Zhu B, Mirabello L

    Cancer 2022; (128(11)):2107-2118 doi:10.1002/cncr.34163.

    PMID: 35226758
  2. 2

    Understanding osteosarcomas.

    Simpson E, Brown HL

    JAAPA : official journal of the American Academy of Physician Assistants 2018; (31(8)):15-19 doi:10.1097/01.JAA.0000541477.24116.8d.

    PMID: 29979330
  3. 3

    Advances in the management of osteosarcoma.

    Bielack SS, Hecker-Nolting S, Blattmann C, Kager L

    F1000Research 2016; (5()):2767 doi:10.12688/f1000research.9465.1.

    PMID: 27990273
  4. 4

    Imaging features at the time of diagnosis of osteosarcoma and Ewing sarcoma in children.

    Moreno-Reina C, Bueno-Gómez M, Guitiérrez-Carrasco JI, Caro-Domínguez P

    Radiologia 2025; (67(3)):253-262 doi:10.1016/j.rxeng.2023.11.003.

    PMID: 40412839
  5. 5

    Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway.

    Saba KH, Difilippo V, Kovac M, et al.

    The Journal of pathology 2024; (262(2)):147-160 doi:10.1002/path.6219.

    PMID: 38010733
  6. 6

    Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

    Lorenz S, Barøy T, Sun J, et al.

    Oncotarget 2016; (7(5)):5273-88 doi:10.18632/oncotarget.6567.

    PMID: 26672768
  7. 7

    TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.

    Chen Z, Guo J, Zhang K, Guo Y

    Disease markers 2016; (2016()):4639575 doi:10.1155/2016/4639575.

    PMID: 27239089
  8. 8

    Multidisciplinary approach to osteosarcoma.

    Biazzo A, De Paolis M

    Acta orthopaedica Belgica 2016; (82(4)):690-698.

    PMID: 29182106
  9. 9

    Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

    Biermann JS, Hirbe A, Ahlawat S, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2025; (23(4)).

    PMID: 40203873
  10. 10

    Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.

    Benjamin RS

    Advances in experimental medicine and biology 2020; (1257()):1-10 doi:10.1007/978-3-030-43032-0_1.

    PMID: 32483726
  11. 11

    Recognizing and treating patients with Ewing sarcoma.

    Windheuser A, Gardner N

    JAAPA : official journal of the American Academy of Physician Assistants 2023; (36(9)):1-4 doi:10.1097/01.JAA.0000937324.58262.55.

    PMID: 37668491
  12. 12

    Bone Cancer: Diagnosis and Treatment Principles.

    Ferguson JL, Turner SP

    American family physician 2018; (98(4)):205-213.

    PMID: 30215968
  13. 13

    Undifferentiated Small Round Cell Sarcomas: Radiologic-Pathologic Correlation for the Updated WHO Classification Fifth Edition (2020).

    Mori K, Kurokawa R, Motoi T, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2026; (46(4)):e250087 doi:10.1148/rg.250087.

    PMID: 41886300
  14. 14

    Epidemiology and Chemosensitivity of Primary Malignant Bone Tumors at a Teaching Hospital in South Africa: A 5-Year Retrospective Analysis.

    Kgagudi MP, Ramokgopa MT, Jingo M

    Medical science monitor : international medical journal of experimental and clinical research 2025; (31()):e948274 doi:10.12659/MSM.948274.

    PMID: 40758634
  15. 15

    New cell lines expanding the diversity of Ewing sarcoma models.

    Kerkhoff M, Schaefer C, Dirks WG, et al.

    International journal of cancer 2026; (158(3)):642-655 doi:10.1002/ijc.70172.

    PMID: 41002248
  16. 16

    The hegemonic EWSR1::ETS oncoprotein overrules core regulatory circuitry principles in Ewing sarcoma.

    Grossetete S, Zaidi S, Orth MF, et al.

    NPJ precision oncology 2025; doi:10.1038/s41698-025-01226-8.

    PMID: 41444391
  17. 17

    One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.

    Flores G, Grohar PJ

    Journal of bone oncology 2021; (31()):100404 doi:10.1016/j.jbo.2021.100404.

    PMID: 34976713
  18. 18

    EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma.

    Hernández-Muñoz I, Cuervas I, Prada E, et al.

    Nature communications 2025; (16(1)):9427 doi:10.1038/s41467-025-64475-y.

    PMID: 41136396
  19. 19

    Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription.

    Kaufman R, Flores G, Boguslawski EA, et al.

    Nature communications 2026; (17(1)).

    PMID: 41698909
  20. 20

    Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.

    Brennan B, Kirton L, Marec-Bérard P, et al.

    Lancet (London, England) 2022; (400(10362)):1513-1521 doi:10.1016/S0140-6736(22)01790-1.

    PMID: 36522207
  21. 21

    Systemic treatment for primary malignant sarcomas arising in craniofacial bones.

    Bielack SS

    Frontiers in oncology 2022; (12()):966073 doi:10.3389/fonc.2022.966073.

    PMID: 36158667
  22. 22

    Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes.

    Sand LG, Szuhai K, Hogendoorn PC

    International journal of molecular sciences 2015; (16(7)):16176-215 doi:10.3390/ijms160716176.

    PMID: 26193259
  23. 23

    Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.

    Fukushima T, Ogura K, Akiyama T, et al.

    BMC musculoskeletal disorders 2018; (19(1)):297 doi:10.1186/s12891-018-2217-1.

    PMID: 30121085
  24. 24

    Chondrosarcoma of the hyoid bone: A diagnostic pitfall in the submandibular region.

    Rito M, Cabrera RA

    Diagnostic cytopathology 2015; (43(11)):933-6 doi:10.1002/dc.23328.

    PMID: 26304473
  25. 25

    Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials.

    Zając W, Dróżdż J, Kisielewska W, et al.

    Cancers 2023; (15(15)) doi:10.3390/cancers15153924.

    PMID: 37568740

This page explains bone sarcoma subtypes for educational purposes only. Your oncologist and orthopedic surgeon are the best sources for discussing your specific diagnosis and treatment options.

Get notified when new evidence is published on Bone sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.